StemCell Therapy

We will be comparing the differences between Cellect Biotechnology Ltd. (NASDAQ:APOP) and Vaxart Inc. (NASDAQ:VXRT) as far as dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Demonstrates Cellect Biotechnology Ltd. and Vaxart Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 represents Cellect Biotechnology Ltd. (NASDAQ:APOP) and Vaxart Inc. (NASDAQ:VXRT)s return on assets, return on equity and net margins.

Insider and Institutional Ownership

Roughly 0% of Cellect Biotechnology Ltd. shares are held by institutional investors while 34.2% of Vaxart Inc. are owned by institutional investors. About 54.73% of Cellect Biotechnology Ltd.s share are held by insiders. Competitively, Vaxart Inc. has 3.2% of its share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Cellect Biotechnology Ltd.s stock price has bigger decline than Vaxart Inc.

Summary

Cellect Biotechnology Ltd. beats Vaxart Inc. on 6 of the 9 factors.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.

Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Link:
Contrasting of Cellect Biotechnology Ltd. (APOP) and Vaxart Inc. (NASDAQ:VXRT) - MS Wkly

This entry was posted on October 16, 2019 at 4:45 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |